稿源：津滨网 编辑：王宁 2020-03-31 09:16
The Tianjin International Joint Academy for Biomedicine (hereinafter referred to as the "TJAB") located in Tianjin Binhai New Area (TBNA for short) has responded rapidly to the national and Tianjin prevention and control deployment since the outbreak of the COVID-19, and has made every effort to prevent and control the epidemic, while actively supporting the resumption of work and production of enterprises being incubated. At present, all enterprises in the TJAB have resumed work, and the rate of returning to work has reached 100%.
Strict prevention and control contributes to resumption of work and production.
Tianjin Yingtiancheng Technology Co., Ltd. is a dispatched agency of Hebei Tiancheng Pharmaceutical in the TJAB. On March 26, the reporter came to the company located on the 16th floor of the TJAB to see that its R & D personnel are currently on the job, and equipment and projects have begun operation. "At present, we have begun to resume work, and there are seven or eight R & D projects being implemented at the same time." The relevant person in charge of the company told reporters that these projects are related to COVID-19. At present, there is no specific medicine for the treatment of COVID-19, and the world is conducting broad-spectrum screening. The drugs developed by the company are also in the scope of screening, and have now reached the pilot stage.
The ability to resume work quickly and invest in new drug development is inseparable from the strong help of the TJAB. "The TJAB has been guiding companies to resume work and production under epidemic prevention and control." The company's official said that the TJAB has formulated an epidemic prevention and control plan, which is implemented by all enterprises. At the same time, the TJAB also connects companies with procurement channels for epidemic prevention materials to meet their resumption of work. In addition, the TJAB has also established a WeChat group, where companies put forward demands in the group, and it will respond quickly to provide assistance to enterprises.
Huang Yalou, secretary of the party committee of the TJAB, said in an interview with reporters that the TJAB strictly controls the COVID-19 epidemic. When entering the building, one need to wear a mask, strictly scan the code, measure the temperature, verify, and register. Considering the large number of units and dense staff in the building, the layout of the space was optimized in the lobby of the first floor of the experimental building. The overall situation of the staff who came to the TJAB on that day is summarized daily after work and the information is reported. At the same time, through the in-hospital broadcast system, safety management requirements and precautions were broadcast multiple times, and safety reminders and trainings were done.
Innovative investment methods
While the TJAB continued to strengthen the epidemic prevention deployment, raise the awareness of all staff on prevention and control, and build a "firewall" for resumption of work, the project investment and talent team introduction work did not stop.
In the prevention and control of the COVID-19 epidemic, Jingtiancheng Biotechnology (Beijing) Co., Ltd. successfully developed a well-known domestic antibody drug for the COVID-19 diagnostic antibody, which became famous for a while. “In fact, we have contacted Jingtiancheng Biotechnology (Beijing) Co., Ltd. before knowing that this company has the intention to settle down, and quickly opened the cloud investment model to help it complete the registration in the TJAB.” Huang Yalou told reporters that a VR video system previously produced by the TJAB helped a lot in the investment promotion work during the epidemic prevention and control.
According to Huang Yalou, this set of VR video system incorporates the image information of the TJAB's office environment and platform equipment. During the epidemic prevention and control period, due to the inability to conduct field inspections, companies can experience the TJAB through this system, as well as the strength of the hospital, and achieve online housing selection, while completing registration. According to the plan, Jingtiancheng Biotechnology (Beijing) Co., Ltd. will also set up an R & D and testing platform after it is settled to continue to provide key technical support for disease control departments to respond to major epidemics.
Huang Yalou said that next, while strengthening the prevention and control of the epidemic, the TJAB will continue to grasp the social needs and new trends in industrial development, better serve existing enterprises, provide efficient investment promotion services and strive to achieve new development breakthrough.